Related Experiment Video
Updated: Apr 19, 2026
Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions
Published on: April 21, 2016
ApoA-I mimetics
R M Stoekenbroek1, E S Stroes, G K Hovingh
1Department of Vascular Medicine, Academic Medical Center, 22660, 1100 DD, Amsterdam, The Netherlands.
Insights
High-density lipoprotein cholesterol (HDL-C) levels do not always correlate with cardiovascular disease (CVD) risk reduction. Focus is shifting to improving HDL functionality, particularly apolipoprotein A-I (ApoA-I) mimetics, for better therapeutic outcomes.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Pharmacology
Background:
- Plasma high-density lipoprotein cholesterol (HDL-C) levels are inversely associated with cardiovascular disease (CVD) risk.
- Despite this, therapies targeting increased HDL-C levels have not consistently reduced CVD outcomes.
- This necessitates a shift towards strategies that enhance HDL functionality.
Purpose of the Study:
- To explore the role of apolipoprotein A-I (ApoA-I) in HDL's antiatherogenic functions.
- To review therapies designed to mimic ApoA-I function, including ApoA-I mimetic peptides.
- To assess the potential of ApoA-I mimetics in treating atherosclerosis and other conditions.
Main Methods:
- Review of existing clinical trial data on HDL-C-raising therapies.
- Analysis of the role of ApoA-I in reverse cholesterol transport (RCT).
- Examination of ApoA-I mimetic peptides and their mechanisms of action.
Main Results:
- Clinical trials targeting increased HDL-C levels have yielded disappointing results for CVD outcomes.
- ApoA-I is crucial for HDL's antiatherogenic properties, including RCT.
- ApoA-I mimetics show promise due to their ability to mimic ApoA-I function and potential anti-inflammatory effects.
Conclusions:
- Therapeutic strategies should focus on improving HDL functionality rather than solely increasing HDL-C levels.
- ApoA-I mimetics represent a promising therapeutic avenue for cardiovascular disease.
- The anti-inflammatory properties of ApoA-I mimetics suggest broader therapeutic applications beyond atherosclerosis.
Abstract:
A wealth of evidence indicates that plasma levels of high-density lipoprotein cholesterol (HDL-C) are inversely related to the risk of cardiovascular disease (CVD). Consequently, HDL-C has been considered a target for therapy in order to reduce the residual CVD burden that remains significant, even after application of current state-of-the-art medical interventions. In recent years, however, a number of clinical trials of therapeutic strategies that increase HDL-C levels failed to show the anticipated beneficial effect on CVD outcomes. As a result, attention has begun to shift toward strategies to improve HDL functionality, rather than levels of HDL-C per se. ApoA-I, the major protein component of HDL, is considered to play an important role in many of the antiatherogenic functions of HDL, most notably reverse cholesterol transport (RCT), and several therapies have been developed to mimic apoA-I function, including administration of apoA-I, mutated variants of apoA-I, and apoA-I mimetic peptides. Based on the potential anti-inflammatory effects, apoA-I mimetics hold promise not only as anti-atherosclerotic therapy but also in other therapeutic areas.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
02:15Experimental RNAi
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
01:29Pharmacogenomics: Identification of New Drug Targets